viernes, 28 de agosto de 2015

Ratón de Biblioteca: !Despierta Farmacia! / Luis de la Fuente (Almirall)

Antigua Libreria Almirall*


Para que abras los ojos a todas las oportunidades de negocio: Presentamos el libro “¡Despierta, Farmacia!” 

En tiempos de dificultad económicas, desde el Club de la Farmacia queremos ayudar a las Farmacias a reactivar la rentabilidad de sus negocios gracias a un nuevo método de gestión. Para ello lanzamos el libro “¡Despierta, Farmacia!” que ya hemos presentado con gran éxito en INFARMA 2014. 

Se trata de un manual que permite identificar, integrar y aprovechar el potencial de negocio de 4 áreas de la Farmacia mediante el Método GUN (Gestión por Unidad de Negocio).

  • Producto
  • Superficie de ventas
  • Equipo
  • Consumidor
 El trabajo con el GUN permite gestionar la farmacia como un conjunto de negocios interdependiente entre si, obteniendo un equipo implicado y motivado, una exposición y un surtido coherente y acertado, una circulación con sentido y razón y unos clientes satisfechos que repetirán la experiencia de compra.

Con el auspicio de Almirall

(*) En la calle Princesa, una placa en el pavimento aún recuerda a la bicentenaria librería Almirall, fundada en 1733, aunque alberga a la estilosa panadería ecológica Barcelona–Reykjavik. (Ver)

jueves, 27 de agosto de 2015

The Pharma China Syndrome

China slowdown for pharma shouldn't be ignored, WSJ says August 24, 2015 | By EJ Lane

The widely reported slowdown in sales in China noted across most multinational pharma companies deserves a harder look, the Wall Street Journal says. 



The WSJ said that overall emerging-market sales for the biggest firms tracked by Sanford C. Bernstein increased by about 5.5% for the year ended the second quarter well below a 9% average in the previous four quarters. 

The slowdown in China was blamed on tighter terms and competition in tenders and a shift in the way sales channels work at big hospitals and via doctors as Beijing pursues reforms aimed at cutting growing healthcare costs. 

Those trends were compounded this month when China surprised markets and revalued the yuan, the WSJ said, with a knock-on effect in other emerging markets which compete with China in trade on narrow margins easily hit by currency volatility. 

 According to the WSJ, emerging markets make up a sizeable amount of revenues for multinational firms, particularly for Europeans companies, citing 34% of sales at Sanofi and 26% at Novartis.

Ver: 

Fin del al_BRIC_ias...!!!


The newspaper said that of note was the emphasis on sales of new products in China over traditional products, citing an example of Bayer's new blood thinner Xarelto

Among major companies operating in China, Pfizer saw a 3% drop in constant currency in the second quarter in China, compared to a gain of 12% in the first quarter for a firm that has a high-profile joint venture with Hisun. For European firms, Roche saw a 1% gain in constant currency in the second quarter, from a 12% burst in the first quarter.  (Ver)

martes, 25 de agosto de 2015

Orgasmos de...$US 1 billon los de Sprout Addyi para Valeant.


Canada's Valeant Pharmaceuticals International Inc  said on Thursday it would buy Sprout Pharmaceuticals, which makes a controversial new drug to treat low sexual desire in women, for about $1 billion

Valeant shares fell about 5 percent as Wall Street questioned whether the acquisition would be too risky for the big drugmaker, which has done six other deals this year. 


The U.S. Food and Drug Administration approved Sprout's Addyi on Tuesday after rejecting it twice. The pink pill proved only marginally effective in clinical trials and carries a strong warning about potentially dangerous low blood pressure and fainting, especially when taken with alcohol. 

 "Although the drug has a potentially large addressable patient population and will benefit from the marketing scale of Valeant’s sales force, acceptance of this product may ultimately be limited," Morningstar Research analyst Michael Waterhouse said. Health insurers may not cover the drug, he added. 

From PharmaGuy
While Addyi has been nicknamed "female Viagra," it works differently from Pfizer Inc's  product, which was introduced nearly two decades ago as the first drug for erectile dysfunction. Addyi is meant to activate sexual impulses in the brain and is taken daily, while Viagra affects blood flow and is taken as needed. 

Valeant will pay $500 million now and $500 million early next year in cash, delaying the company's plans to reduce debt from its $800 million purchase of Amoun Pharmaceutical announced last month and its $11 billion acquisition of Salix Pharmaceuticals, Moody's Investors Service said. Including Sprout, the company has done $18.2 billion in deals so far this year. 

Addyi's prospects are anything but certain, said Raghuram Selvaraju, managing director of brokerage Wainwright & Co. (Más)

 
Firstly, where does a Canadian pharmaceutical company come up with one billion dollars? 
Secondly, how long will it take to recoup that and other costs associated with selling Addyi and start to make a profit? 

 Obviously, Valeant is more confident in the drug’s success than is Public Citizen's Dr. Sidney Wolfe, who said the drug’s approval “recklessly disregards the worrisome risk information” and who predicts Addyi will have to be taken off the market after enough women have been seriously harmed by the “irreversible, or life threatening injuries” caused by the drug (read "Wolfe Disapproves, but 'Wolf' Approves FDA Decision re ADDYI"). 

Wolfe et al have a good track record predicting which drugs will eventually be pulled from the market due to safety issues. Read, for example, "Sydney Wolfe's 7-Year Drug Rule/Itch: Don't Prescribe or Imbibe Any New Drug for First Seven Years After FDA Approval."

Ver
One Billion Dollars! O Valeant! Sung to tune of O Canada!

Ver también:
Valeant compra al fabricante de la «viagra femenina» un día después de su aprobación

Toda la "historia de Addyi" en PHARMACOSERÍAS

domingo, 23 de agosto de 2015

Píldoras "al dron"...



Activistas de ONG holandesas, alemanas y polacas denunciaron este sábado las dificultades para acceder al aborto en Polonia con el envío a este país desde Alemania de un dron que transportaba píldoras del día después. 

El pequeño aparato partió de la ciudad alemana de Fráncfort del Oder y cruzó el río que hace de frontera con el país vecino para aterrizar en la localidad polaca de Slubice. 

La acción estuvo organizada por la ONG holandesa Women on Waves, conocida por haber facilitado a mujeres de distintos países abortos en un barco-clínica fondeado en aguas internacionales, además de Ciocia Basia, que facilita la interrupción voluntaria del embarazo en Berlín a mujeres polacas, y la fundación polaca Feminteka. 

"La actual y restrictiva ley del aborto polaca genera injusticia social y afecta especialmente a las mujeres sin medios económicos o sin información", denunciaron estas organizaciones en un comunicado tras concluir su acción de protesta. 

La legislación polaca permite abortar si hay riesgo para la vida o la salud de la madre, si el embarazo es el resultado de una violación o si el feto presenta graves malformaciones, una normativa que estas organizaciones tachan de restrictiva y que se une a la negativa de muchos médicos a practicar abortos. 

Como muestra de ello, recordaron que frente a las 99.700 interrupciones voluntarias del embarazo registradas el año pasado en Alemania, con alrededor de 80 millones de habitantes, en Polonia, con 38 millones, se realizaron sólo 744 abortos, cifra que oculta, a su juicio, decenas de miles de intervenciones clandestinas. 

Ver:

Sky-rocketing the right to safe abortion: between borders and drones

Según habían explicado con anterioridad las organizadoras, su acción no necesitaba contar con ningún tipo de autorización administrativa previa, aunque este sábado denunciaron que la policía alemana confiscó los mandos de control del dron entre otro material.